drugset / Trial / NCT00150748

Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

NCT00150748

Phase 3 Completed 217 enrolled UCB Pharma
NaSingle-groupOpen-labelTreatment

Summary

An open-label, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV), in children (≥ 4 years old), adolescents and adults suffering from primary generalized seizures.

Timeline

Start
2001-11
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 166 mg Oral
Subject Levetiracetam Other / unclassified 250 mg Oral
Subject Levetiracetam Other / unclassified 500 mg Oral

Indications